RedHill Biopharma Ltd (RDHL) has released an update.
RedHill Biopharma Ltd. has reported a significant corporate transformation, focusing on U.S. government-funded R&D for medical countermeasures and treatments for underserved medical areas, such as Acute Radiation Syndrome, Ebola, and COVID-19, with an emphasis on strategic business transactions and asset divestment. The company’s two lead drugs, opaganib and RHB-107, have shown promise in pre-clinical testing and are entering advanced clinical development. Financially, RedHill ended 2023 with a gross profit of $3.1 million and an operating income of $12.6 million, reflecting a strong turnaround from the previous year’s operating loss.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
